Kymera Therapeutics, Inc., together with its subsidiary, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, which are in Phase I and IND-enabling respectively. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Kymera Therapeutics, Inc.

Stifel Nicolaus analyst Alex Thompson CFA maintained a Buy rating on Kymera Therapeutics today and set a price target of $132.00. According to TipR...

Kymera Therapeutics (KYMR) Receives a Rating Update from a Top Analyst

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Metagenomi, Inc. (MGX) and Kymera Therapeutics (KYMR...

Analysts’ Top Healthcare Picks: Metagenomi, Inc. (MGX), Kymera Therapeutics (KYMR)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Korro Bio (KRRO), Ardelyx (ARDX) and Kymera Therapeutics (KYMR). ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	KYMR	$121.41	+3.42%	704.51K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	KYMR	$121.41	+3.4%	704.51K
3
4
5
6

KYMR

Get Kymera Therapeutics, Inc. Data in Excel

Get Kymera Therapeutics, Inc. Data in Excel